A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century

Author:

Wang Jingyu1ORCID,Zhao Wenling2,Zhang Zhao1,Liu Xingzi1,Xie Tong1,Wang Lan1,Xue Yuzhou3,Zhang Yuemiao1ORCID

Affiliation:

1. Renal Division Peking University First Hospital Peking University Institute of Nephrology Key Laboratory of Renal Disease Ministry of Health of China Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University) Ministry of Education Beijing 100034 China

2. Beijing National Laboratory for Molecular Sciences CAS Laboratory of Colloid and Interface and Thermodynamics CAS Research/Education Center for Excellence in Molecular Sciences Center for Carbon Neutral Chemistry Institute of Chemistry Chinese Academy of Sciences Beijing 100190 China

3. Department of Cardiology Institute of Vascular Medicine NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides State Key Laboratory of Vascular Homeostasis and Remodeling Peking University Beijing Key Laboratory of Cardiovascular Receptors Research Peking University Third Hospital Beijing 100191 China

Abstract

AbstractNanotechnology profoundly affects the advancement of medicine. Limitations in diagnosing and treating cancer and chronic diseases promote the growth of nanomedicine. However, there are very few analytical and descriptive studies regarding the trajectory of nanomedicine, key research powers, present research landscape, focal investigative points, and future outlooks. Herein, articles and reviews published in the Science Citation Index Expanded of Web of Science Core Collection from first January 2000 to 18th July 2023 are analyzed. Herein, a bibliometric visualization of publication trends, countries/regions, institutions, journals, research categories, themes, references, and keywords is produced and elaborated. Nanomedicine‐related academic output is increasing since the COVID‐19 pandemic, solidifying the uneven global distribution of research performance. While China leads in terms of publication quantity and has numerous highly productive institutions, the USA has advantages in academic impact, commercialization, and industrial value. Nanomedicine integrates with other disciplines, establishing interdisciplinary platforms, in which drug delivery and nanoparticles remain focal points. Current research focuses on integrating nanomedicine and cell ferroptosis induction in cancer immunotherapy. The keyword “burst testing” identifies promising research directions, including immunogenic cell death, chemodynamic therapy, tumor microenvironment, immunotherapy, and extracellular vesicles. The prospects, major challenges, and barriers to addressing these directions are discussed.

Funder

National Natural Science Foundation of China

Beijing Nova Program

Natural Science Foundation of Beijing Municipality

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3